Corrigendum to “KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study” [Leuk. Res. 50 (Nov) (2016) 123–131. PubMed PMID: 27736729]

Ronan T Swords; Peter L Greenberg; Andrew H Wei; Simon Durrant; Anjali S Advani; Mark S Hertzberg; Ian D Lewis; Gabriel Rivera; Dita Gratzinger; Alice C Fan; Dean W Felsher; Jorge E Cortes; Justin M Watts; Geoff T Yarranton; Jackie M Walling; Jeffrey E Lancet

doi:10.1016/j.leukres.2017.02.007

Back

Corrigendum to “KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study” [Leuk. Res. 50 (Nov) (2016) 123–131. PubMed PMID: 27736729]

Journal article

Peer reviewed

Corrigendum to “KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study” [Leuk. Res. 50 (Nov) (2016) 123–131. PubMed PMID: 27736729]

Ronan T Swords, Peter L Greenberg, Andrew H Wei, Simon Durrant, Anjali S Advani, Mark S Hertzberg, Ian D Lewis, Gabriel Rivera, Dita Gratzinger, Alice C Fan, …

Leukemia research, Vol.59, pp.65-65

2017-08

DOI: https://doi.org/10.1016/j.leukres.2017.02.007

PMID: 28575698

Metrics

6 Record Views

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration; International collaboration
Citation topics: 1 Clinical & Life Sciences; 1.5 Neuroscience; 1.5.826 Axon Guidance
Web Of Science research areas: Hematology; Oncology
ESI research areas: Clinical Medicine

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites

Details

Title: Corrigendum to “KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study” [Leuk. Res. 50 (Nov) (2016) 123–131. PubMed PMID: 27736729]
Creators: Ronan T Swords - Leukemia Program, Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, FL, United States
Peter L Greenberg - Stanford Cancer Institute, Stanford, CA, United States
Andrew H Wei - The Alfred Hospital and Monash University, Melbourne, Australia
Simon Durrant - The Royal Brisbane and Women's Hospital, Brisbane, Australia
Anjali S Advani - Cleveland Clinic, Cleveland, OH, United States
Mark S Hertzberg - Westmead Hospital, Westmead, Australia
Ian D Lewis - The Royal Adelaide Hospital, Adelaide, Australia
Gabriel Rivera - Stanford Cancer Institute, Stanford, CA, United States
Dita Gratzinger - Stanford Cancer Institute, Stanford, CA, United States
Alice C Fan - Stanford Cancer Institute, Stanford, CA, United States
Dean W Felsher - Stanford Cancer Institute, Stanford, CA, United States
Jorge E Cortes - The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Justin M Watts - Leukemia Program, Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, FL, United States
Geoff T Yarranton - KaloBios Pharmaceuticals, Inc., South San Francisco, CA, United States
Jackie M Walling - KaloBios Pharmaceuticals, Inc., South San Francisco, CA, United States
Jeffrey E Lancet - H Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
Publication Details: Leukemia research, Vol.59, pp.65-65
Publisher: Elsevier Ltd
Academic Unit: Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
Language: English
Resource Type: Journal article
PMID: 28575698
Record Identifier: 991031597719002976